Slide 1: FY 2025 Results Presentation
• FY 2025 RESULTS PRESENTATION • March 26th, 2026
Slide 2: Executive Summary
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Executive Summary FY 2025 key trends and figures FY 2025 Sales at €424.7m, +2.0% excluding FX vs. FY 2024 €107m adjusted EBITDA in FY 2025, +3.0% vs. previous y
Slide 3: FY 2025 Results At-a-Glance
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2025 Results At-a-Glance Growing profitability, despite adverse FX and weak US dialysis contribution SALES Adjusted EBITDA and % Net Financial Position and L
Slide 4: Sales – FY 2025 vs. FY 2024
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Sales – FY 2025 vs. FY 2024 +2.0% YoY growth excl. FX, supported by M&A contribution and pricing SALES – FY 2024 TO FY 2025 BRIDGE €m 428.5 • +2.0% growth excl.
Slide 5: Sales Performance by Division
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Sales – FY 2025 Performance by Division Safety division leading Group’s sales growth Healthcare & Life Sciences Safety Energy & Mobility €m €m €m Excl. FX Excl.
Slide 6: Adj. EBITDA – FY 2025 vs. FY 2024
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Adj. EBITDA – FY 2025 vs. FY 2024 95 bps of margin expansion, supported by pricing ADJ. EBITDA – FY 2024 TO FY 2025 BRIDGE €m 24.3% ADJUSTED EBITDA % 25.2% 95bp
Slide 7: Adj. Net Income – FY 2025 vs. FY 2024
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Adj. Net Income – FY 2025 vs. FY 2024 +5.9% YoY growth excl. FX impact Adj. Net Income Adj. Net Income Excl. FX Gains/Losses €m €m +5.9% 47.4 47.7 44.8 31.9 11.
Slide 8: Net Financial Position – FY 2025 vs. FY 2024
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Net Financial Position – FY 2025 vs. FY 2024 Leverage at 2.2x post Whole Blood acquisition NET FINANCIAL POSITION – FY 2024 TO FY 2025 BRIDGE €m 2.1x LEVERAGE R
Slide 9: FY 2026 – Strategic Focus and Guidance
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2026 – Strategic Focus and Guidance Focus on Organic Growth post M&A integration • MedTech: Establish new subdivisions to sharpen commercial focus on higher-
Slide 10: FY 2025 Results – Financial Statements
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2025 Results – Financial Statements FY 2024 and FY 2025 P&L – Statutory Adjusted View of which FY 2024 of which FY 2025 €m FY 2024 % FY 2025 % non-recurring
Slide 11: FY 2025 Results – Financial Statements
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2025 Results – Financial Statements Reclassified Balance Sheet - FY 2024 – FY 2025 As of As of €m 31-Dec-2024 31-Dec-2025 Net intangible fixed assets 472.9 4
Slide 12: FY 2025 Results – Financial Statements
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2025 Results – Financial Statements Cash Flow Statement – FY 2024 – FY 2025 €m FY 2024 FY 2025 Pre-tax result 43.0 25.8 Amortisation, depreciation and writed
Slide 13: Disclaimer
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Disclaimer Pursuant to art. 154-bis, paragraph 2, of the Italian Unified Financial Act of February 24, 1998, the executive in charge of preparing the corporate